TERT mRNA Vector Composition for Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mutations and deletions can cause mis-expression of genes, leading to the need for therapies that correct the misexpression of specific genes.
Innovation Solution
Compositions comprising a plasmid with nucleotide sequences that encode for mRNA, which when introduced into cells, increase the production of target biomolecules like telomerase reverse transcriptase (TERT) through recombinant plasmids and gene vectors, utilizing adeno-associated virus vectors or protein coats for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If gene vectors containing nucleotide sequences are administered to increase endogenous production of mRNA, then the bioavailability of target biomolecule is improved, but the complexity of the therapy increases
Solution Approach 1:
The patent uses gene vectors as intermediary carriers to deliver nucleotide sequences into cells. These vectors act as mediators that facilitate the transfer of genetic material from the administered composition to the target cells, enabling increased endogenous production of mRNA without direct manipulation of cellular machinery. This intermediary approach resolves the contradiction by providing a controlled delivery mechanism that achieves the desired biochemical effect while managing therapeutic complexity.
Solution Approach 2:
The therapy employs preliminary action by administering compositions that contain pre-assembled gene vectors with nucleotide sequences designed to increase endogenous mRNA production. Rather than attempting to directly manipulate gene expression mechanisms within cells, the therapeutic composition is prepared in advance with all necessary components (nucleotide sequences, vector structures, regulatory elements) already configured to achieve the desired effect once introduced into the subject.
2Productivity
If plasmids with insert sequences are introduced into cells to increase target mRNA expression, then the production of target biomolecule is improved, but the difficulty of delivering the composition to target cells increases
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical properties of the composition to enhance cellular uptake. This includes optimizing parameters such as plasmid structure, nucleotide sequence configuration, and vector composition to improve delivery efficiency. By adjusting these parameters, the therapy achieves better cellular penetration and expression levels while managing the inherent difficulties of delivering large nucleic acid molecules into target cells.
3Reliability
If recombinant plasmids are used to increase endogenous production of mRNA sequences, then the functionality of target biomolecule is improved, but the manufacturing complexity increases
Solution Approach 1:
The recombinant plasmid composition is segmented into distinct functional components: backbone sequences that facilitate cellular introduction and replication, and insert sequences that encode the desired mRNA production. This segmentation allows each component to be optimized and manufactured separately using established molecular biology techniques, then assembled into the complete therapeutic composition. This modular approach improves reliability of the final product while making the manufacturing process more manageable through standardized assembly procedures.
Data Source
AI summary
Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a protein such as TERT.